The content on this site is intended for healthcare professionals only
Pierre Fouret, MD, PhD, Institut Gustave Roussy, Université Pierre et Marie Curie, Paris, France: Speaking at ASCO 2009: Lung Cancer Patients Lacking MSH2 DNA Repair Protein Fare Better with Chemotherapy: An analysis from the International Adjuvant Lung Trial (IALT) reports that tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy among patients with surgically removed non-small cell lung cancer (NSCLC). MSH2 is a protein that cancer cells use to repair DNA damaged by cisplatin. Researchers found that patients with no or low levels of the MSH2 protein respond better to treatment than patients with high levels.
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
